Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis Falls Despite Earnings Beat, Guidance Raise
10:51am, Thursday, 18'th Jul 2024
Novartis (NVS) American depositary receipts (ADRs) slipped Thursday even though the pharmaceutical giant beat second-quarter earnings expectations and raised its full-year core operating income guidan
Novartis (NVS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
10:36am, Thursday, 18'th Jul 2024
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
2 Healthcare Stocks For Your Mid-July 2024 Watchlist
09:38am, Thursday, 18'th Jul 2024
Healthcare stocks to check out in the stock market right now.
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
09:25am, Thursday, 18'th Jul 2024
Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.
2 Magnificent Stocks to Buy With $500
04:59am, Thursday, 18'th Jul 2024
Merck's long-term prospects look strong despite a major incoming patent cliff. Novartis' diversified lineup and pipeline, solid results, and dividend record make it an excellent pick.
Novartis raises 2024 profit guidance for second time
01:17am, Thursday, 18'th Jul 2024
Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions of drugs including heart failure treatment Entresto and Kesimpta for multi
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
01:00am, Thursday, 18'th Jul 2024
Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1 , +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (
3 Global Stocks to Buy to Escape the Volatility on Wall Street
07:34am, Tuesday, 16'th Jul 2024
U.S. stock indices have reached new highs, driven by strong corporate earnings, especially in technology. Meanwhile, many non-U.S. stocks have lagged so far in 2024.
Here's Why Novartis (NVS) is a Strong Value Stock
10:41am, Monday, 15'th Jul 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis Q2 Earnings Preview: Positive Fundamental Trends Should Continue
10:09am, Monday, 15'th Jul 2024
Novartis AG will report second quarter results this week. The company should report another strong quarter, with growth led by key products such as Entresto, Kesimpta, Kisqali, Cosentyx, and Leqvio. I
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
11:00am, Saturday, 13'th Jul 2024
Over the years, especially the past three, I have become more cautious about the technology sector's blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such a
3 Healthcare Stocks Injecting AI for Big Gains
06:26am, Saturday, 13'th Jul 2024
While the pairing of artificial intelligence and healthcare may sound like something straight out of a science fiction movie, there are several avenues through which the high-speed data processing off
10 Dividend Aristocrat Bargain Buys: High Yields And Low PEG Ratios
07:00am, Friday, 12'th Jul 2024
Stocks keep setting record highs, with valuations becoming steadily more challenging. But even at record highs, there are plenty of blue-chip bargains to buy. Free cash flow yield is a gold standard o
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
06:15am, Friday, 12'th Jul 2024
Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless
Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch
08:33am, Tuesday, 09'th Jul 2024
Immunic Inc (NASDAQ:IMUX) told investors it has appointed a former Novartis and Biogen executive as its new chief operating officer to lead internal efforts to prepare for the potential launch of v
